logo
Karman Space & Defense Acquires Industrial Solid Propulsion ('ISP'), a Leading Supplier of Energetic Propulsion Technologies for Next-Generation UAS, UAS Intercept and Rocket-Assisted Takeoff Systems

Karman Space & Defense Acquires Industrial Solid Propulsion ('ISP'), a Leading Supplier of Energetic Propulsion Technologies for Next-Generation UAS, UAS Intercept and Rocket-Assisted Takeoff Systems

Business Wire4 days ago

HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)-- Karman Space & Defense ('Karman', 'Karman Holdings, Inc.' or 'the Company') (NYSE: KRMN), a leader in the rapid design, development and production of critical, next-generation system solutions for launch vehicle, satellite, spacecraft, missile defense, hypersonic and UAS customers today announced it has acquired ISP, a leader in specialty energetic propulsion technologies including small boost motors and solid propellant gas generators for the rapidly growing UAS, UAS intercept and rocket-assisted takeoff systems markets. The transaction closed on May 28, 2025.
"This acquisition strengthens our core competency in energetics, expands our offering in small-diameter solid propellant technologies and will allow us to serve our customers even better," said Karman CEO Tony Koblinski
Share
Founded in 1983 and based in Cedar City, Utah, ISP has developed a proprietary portfolio of propellant formulations and tactical motor configurations, with proven flight heritage across a number of high-priority U.S. Department of Defense ('DOD') programs. ISP designs, tests, qualifies and manufactures small-diameter energetic and propulsion systems to meet mission requirements for distance, total impulse, peak thrust and burn time. With the required engineering and manufacturing capabilities to take a product from concept-to-production, ISP is a proven partner to prime customers in delivering integrated energetic and propulsion systems, with more than 40 years of flight heritage.
'We have been working collaboratively with ISP on a number of exciting opportunities for many months and believe that ISP is a natural, strategic fit within the Karman portfolio,' said Tony Koblinski, Karman Chief Executive Officer. 'This acquisition strengthens our core competency in energetics, expands our offering in small-diameter solid propellant technologies and will allow us to serve our customers even better. ISP's proprietary portfolio of propellant formulations and unique manufacturing capabilities furthers Karman's mission of leveraging advanced technologies to drive agile solutions for customers across the space and defense market. We welcome the talented ISP team to Karman and look forward to working together to deliver even more value to our customers.'
ISP leverages its leading IP portfolio and full suite of in-house, small batch manufacturing capabilities to rapidly qualify and deliver efficient, technically optimal energetic systems. ISP's full-service capabilities include propellant and cartridge design, grain formulation, mixing, machining, cartridge loading and hot-fire testing. ISP's propulsion expertise in small-diameter systems and cartridges and its programmatic positions are well aligned with current and future funding priorities, specifically in deployment and launch systems for one-way loitering munitions, counter-UAS and intercept systems.
Additionally, ISP has a long history of supporting STEM-based educational curricula for schools, camps, clubs and youth organizations. Empowering the next generation of energetics and propulsion engineers with tools to help them experiment, learn and launch their careers is central to ISP and highly aligned with Karman's approach to supporting local communities and identifying top talent.
On May 27, 2025, Karman successfully closed an offering to increase the size of its existing $300 million Term Loan B by $75 million. The majority of the proceeds from this offering were used to fund the acquisition of ISP, which consisted of $50 million in cash, approximately $5 million in Karman common shares and $5 million in potential earnout payments.
For more information on ISP, please visit www.specificimpulse.com.
Advisors
Citi served as exclusive financial advisor and Willkie Farr & Gallagher LLP served as legal advisor to Karman in connection with the transaction. KAL Capital served as financial advisor to ISP.
ABOUT KARMAN SPACE & DEFENSE
We specialize in the rapid design, development, and production of next-generation technologies to combat near-peer nation state threats, focused on critical, integrated systems for the hypersonic, missile defense, UAV and space sectors. Our core technology offerings include propulsion, deployable shrouds, launchers, and energetic subsystems. Customers choose our advanced solutions to deliver mission success across a diverse set of existing and emerging programs supporting high-priority defense and commercial space sector initiatives. For more information, visit Karman-SD.com.
Forward-Looking Statements
This announcement may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We intend all forward-looking statements to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by the use of forward-looking words such as 'expect,' 'expectation,' 'believe,' 'anticipate,' 'may,' 'could,' 'intend,' 'belief,' 'plan,' 'estimate,' 'target,' 'predict,' 'likely,' 'seek,' 'project,' 'model,' 'ongoing,' 'will,' 'should,' 'forecast,' 'outlook' or similar terminology. These statements are based on and reflect our current expectations, estimates, assumptions and/ or projections, our perception of historical trends and current conditions, as well as other factors that we believe are appropriate and reasonable under the circumstances. Forward-looking statements are neither predictions nor guarantees of future events, circumstances or performance and are inherently subject to known and unknown risks, uncertainties and assumptions that could cause our actual results to differ materially from those indicated by those statements. There can be no assurance that our expectations, estimates, assumptions and/or projections, including with respect to the future earnings and performance or capital structure of Karman, will prove to be correct or that any of our expectations, estimates or projections will be achieved.
Numerous factors could cause our actual results and events to differ materially from those expressed or implied by forward-looking statements, including the factors described in the filings we make with the SEC from time to time and, without limitation, that a significant portion of our revenue is generated from contracts with the United States military and U.S. military spending is dependent upon the U.S. defense budget; U.S. government contracts are subject to a competitive bidding process that can consume significant resources without generating any revenue; our business and operations expose us to numerous legal and regulatory requirements, and any violation of these requirements could materially adversely affect our business, results of operations, prospects and financial condition; our inability to adequately enforce and protect our intellectual property or defend against assertions of infringement could prevent or restrict our ability to compete; and we have in the past consummated acquisitions and intend to continue to pursue acquisitions, and our business may be adversely affected if we cannot consummate acquisitions on satisfactory terms, or if we cannot effectively integrate acquired operations. Readers are directed to the risk factors identified in the filings we make with the SEC from time to time, copies of which are available free of charge at the SEC's website at www.sec.gov under Karman Holdings Inc.
The forward-looking statements included in this announcement are only made as of the date of this announcement. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable law.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CARMAT Announces the First Commercial Implants of Its Aeson® Artificial Heart Outside the European Union
CARMAT Announces the First Commercial Implants of Its Aeson® Artificial Heart Outside the European Union

Business Wire

time41 minutes ago

  • Business Wire

CARMAT Announces the First Commercial Implants of Its Aeson® Artificial Heart Outside the European Union

PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the ' Company ' or ' CARMAT '), today announces the first implants of its Aeson® artificial heart in a commercial set-up, outside the European Union (EU). Two implants of Aeson® artificial heart were performed during the week commencing May 26, 2025 in Israel. The first one was carried out at Hadassah Ein Kerem Hospital in Jerusalem by a team led by Pr Offer Amir, Pr Rabea Asleh and Dr Amit Korach, respectively director of the Heart Institute, director of heart failure unit and director of the cardiac surgery department at Hadassah Medical Center. The second one was carried out at Sheba Medical Center in Ramat Gan (Tel Aviv), by a team led by Dr Jeff Morgan, Dr Leonid Sternik, Dr Alex Fardman and Dr Eyal Nachum, respectively head of mechanical support unit, director of cardiac surgery department, heart failure cardiologist and cardiac transplant surgeon. Those are the first Aeson® implants made in a commercial set-up outside the European Union. These implants bring to 5 the total number of countries 1 where commercial implants have been performed so far. They confirm the trust placed in the device by healthcare professionals, and the growing interest in the therapy. About CARMAT CARMAT is a French MedTech that designs, manufactures and markets the Aeson ® artificial heart. The Company's ambition is to make Aeson ® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world's first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson ® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson ® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson ® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d'Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956). For more information, please go to and follow us on LinkedIn. Disclaimer This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country. This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the 'AMF') under number D.25-0345 (the ' 2024 Universal Registration Document '), available free of charge on the websites of CARMAT ( and the AMF ( Readers' attention is particularly drawn to the fact that the Company's current cash runway is limited to mid-June 2025 (excluding the flexible equity financing line entered into with IRIS, which was announced on March 27, 2025). The Company is also subject to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the pace and results of ongoing or planned clinical trials, technological evolution and competitive environment, regulatory changes, industrial risks, and all risks associated with the Company's growth management. The Company's forward-looking statements mentioned in this press release may not be achieved due to these elements or other risk factors and uncertainties, whether unknown or not considered material and specific by the Company as of today. Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA).

Elliptic Labs Announces Four Smartphone Model Shipments with vivo and Xiaomi for May 2025
Elliptic Labs Announces Four Smartphone Model Shipments with vivo and Xiaomi for May 2025

Business Wire

time41 minutes ago

  • Business Wire

Elliptic Labs Announces Four Smartphone Model Shipments with vivo and Xiaomi for May 2025

OSLO, Norway--(BUSINESS WIRE)-- Elliptic Labs (OSE: ELABS), a global AI software company and the world leader in AI Virtual Smart Sensors™ currently deployed in over half a billion devices, has shipped its AI Virtual Smart Sensor Platform™ on four smartphone models in May 2025. Xiaomi announced one smartphone: the Xiaomi Civi 5 Pro. vivo shipped three smartphones: the vivo IQOO Z10 Turbo Series and vivo Y300 GT Smartphones. For 2025 year-to-date, Elliptic Labs has launched on a total of 24 smartphone models. 'Elliptic Labs' AI Virtual Smart Sensor Platform was launched on four smartphone models in May 2025, bringing our total to 24 smartphone model launches year-to-date.' - Laila Danielsen, CEO of Elliptic Labs Share 'Elliptic Labs' AI Virtual Smart Sensor Platform was launched on four smartphone models in May 2025, bringing our total to 24 smartphone model launches year-to-date,' said Laila Danielsen, CEO of Elliptic Labs. AI Virtual Proximity Sensor INNER BEAUTY Elliptic Labs' AI Virtual Proximity Sensor detects when a user holds their phone up to their ear during a call, allowing the smartphone to turn off its display and disable its screen's touch functionality. This keeps the user's ear or cheek from triggering unwanted actions during the call, such as hanging up or dialing numbers. Turning off the screen also helps conserve battery life. Proximity detection is a core capability that is used in all smartphones, but Elliptic Labs' AI Virtual Proximity Sensor is a unique, software-only solution that delivers robust proximity detection without the need for a dedicated hardware sensor. By replacing hardware sensors with software sensors, the AI Virtual Proximity Sensor reduces device cost and eliminates sourcing risk. INNER BEAUTY is a registered trademark of Elliptic Labs. AI Virtual Smart Sensor, AI Virtual Proximity Sensor, and AI Virtual Smart Sensor Platform are trademarks of Elliptic Labs. All other trademarks or service markets are the responsibility of their respective organizations. About Elliptic Labs Elliptic Labs' AI Virtual Smart Sensor Platform™ brings contextual intelligence to devices, enhancing user experiences. Our technology uses proprietary deep neural networks to create AI-powered Virtual Smart Sensors that improve personalization, privacy, and productivity. Currently deployed in over 500 million devices, our platform works across all devices, operating systems, platforms, and applications. By utilizing system-level telemetry data to cloud-based Large Language Models (LLMs), the AI Virtual Smart Sensor Platform delivers the unrivaled capability to utilize output data from every available data source. This approach allows devices to better understand and respond to their environment, making technology more intuitive and user-friendly. At Elliptic Labs, we're not just adapting to the future of technology – we're actively shaping it. Our goal is to continue pushing the boundaries of contextual intelligence, creating more intuitive and powerful experiences for users worldwide. Elliptic Labs is headquartered in Norway with presence in the USA, China, South-Korea, Taiwan, and Japan. The company is listed on the Oslo Stock Exchange. Its technology and IP are developed in Norway and are solely owned by the company.

BRMK Investors Have Opportunity to Lead Broadmark Realty Capital Inc. Securities Fraud Lawsuit with the Schall Law Firm
BRMK Investors Have Opportunity to Lead Broadmark Realty Capital Inc. Securities Fraud Lawsuit with the Schall Law Firm

Business Wire

timean hour ago

  • Business Wire

BRMK Investors Have Opportunity to Lead Broadmark Realty Capital Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Broadmark Realty Capital Inc. ('Broadmark' or 'the Company') (NYSE: BRMK) for violations of the federal securities laws . Investors who owned the Company's securities as of the record date of the May 2023 merger between Broadmark and Ready Capital Corporation (NYSE: RC) (the "Merger"), are encouraged to contact the firm before July 28, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company and Ready Capital made false and misleading statements to the market leading up to the Merger. Ready Capital's originated portfolio included borrowers suffering from financial distress due to high interest rates. Ready Capital's markets of operation had an oversupply of multifamily properties, hampering borrower's ability to raise rents. Ready Capital's Current Expected Credit Loss reserves were materially understated due to catastrophic setbacks in a major development project. Ready Capital's financial projections including dividends per share and book value per share had no basis in fact when the Merger was proposed to Broadmark shareholders. Based on these facts, the Company's public statements were false and materially misleading throughout the Merger period. When the market learned the truth about the merger, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store